List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Contact Dermatitis - Overview
Contact Dermatitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Contact Dermatitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Contact Dermatitis - Companies Involved in Therapeutics Development
Aposcience AG
Edesa Biotech Inc
Hapten Sciences Inc
ILiAD Biotechnologies LLC
Signum Dermalogix Inc
Contact Dermatitis - Drug Profiles
APO-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diflucortolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HPT-721 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis [strain BPZE1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIG-1322 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Contact Dermatitis - Dormant Projects
Contact Dermatitis - Discontinued Products
Contact Dermatitis - Product Development Milestones
Featured News & Press Releases
Mar 09, 2021: Edesa Biotech completes enrollment for interim clinical study milestone
Nov 03, 2020: Edesa Biotech achieves enrollment milestone in dermatitis study
May 15, 2020: Contact dermatitis: potential new treatments with biologic drug
Dec 03, 2019: Edesa Biotech reports positive healthy volunteer data and expands Phase 2b Dermatitis Study to patients with Facial Lesions
Oct 21, 2019: Edesa Biotech enrolls first patient in phase 2b dermatitis study
Jul 25, 2019: Edesa Biotech completes manufacturing for upcoming dermatitis study
Jun 20, 2019: Edesa Biotech receives approval to proceed with U.S. clinical study
Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Contact Dermatitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Contact Dermatitis - Pipeline by Aposcience AG, 2021
Contact Dermatitis - Pipeline by Edesa Biotech Inc, 2021
Contact Dermatitis - Pipeline by Hapten Sciences Inc, 2021
Contact Dermatitis - Pipeline by ILiAD Biotechnologies LLC, 2021
Contact Dermatitis - Pipeline by Signum Dermalogix Inc, 2021
Contact Dermatitis - Dormant Projects, 2021
Contact Dermatitis - Discontinued Products, 2021

List of Figures
Number of Products under Development for Contact Dermatitis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

Companies Mentioned
• Aposcience AG
• Edesa Biotech Inc
• Hapten Sciences Inc
• ILiAD Biotechnologies LLC
• Signum Dermalogix Inc